| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.90.5.2385 |
| P698 | PubMed publication ID | 7955198 |
| P2093 | author name string | M Gent | |
| P Stevens | |||
| M N Levine | |||
| J Sicurella | |||
| J S Ginsberg | |||
| M T Nurmohamed | |||
| P Powers | |||
| A A Panju | |||
| B MacKinnon | |||
| P Brill-Edwards | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 2385-2389 | |
| P577 | publication date | 1994-11-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery | |
| P478 | volume | 90 |
| Q33356954 | Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin |
| Q47911391 | Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development |
| Q77901248 | Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis |
| Q33367230 | Bivalirudin: a review |
| Q34585171 | Bivalirudin: a review of its potential place in the management of acute coronary syndromes |
| Q77297306 | Cardiovascular chemotherapy: anticoagulants |
| Q36034723 | Current concepts for the prevention of venous thromboembolism |
| Q41332329 | Developments in antithrombotic therapy: state of the art anno 1996. |
| Q34196142 | Direct and indirect antithrombins. Heparins, low molecular weight heparins, heparinoids, and hirudin |
| Q56003309 | Direct thrombin inhibitors |
| Q48221402 | Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps |
| Q33637663 | Mechanisms of antithrombotic drugs |
| Q24681351 | New anticoagulants for the prevention and treatment of venous thromboembolism |
| Q71917644 | Penile replantation using the leech Hirudo medicinalis |
| Q34733975 | Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin |
| Q28346958 | Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease |
| Q33785418 | Preventing thromboembolic complications in older orthopaedic surgery patients: interventions and outcomes |
| Q33496843 | Prevention and treatment of venous thromboembolism |
| Q73433630 | Prevention of venous thromboembolism |
| Q33359976 | Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors |
| Q44026185 | Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies |
| Q40409337 | The therapeutic potential of novel anticoagulants |
| Q52533632 | Therapeutic inhibition of thrombin activities, receptors, and production. |
| Q31042575 | Treatment of heparin-induced thrombocytopenia |
| Q74409655 | Treatment of venous thromboembolism in cancer patients |
| Q38053898 | Venous thromboembolism: diagnosis and current anticoagulation strategies for deep vein thrombosis and pulmonary embolism |
| Q44217663 | Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial |
| Q73446080 | [Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis] |
Search more.